AbbVie subsidiary Allergan Aesthetics has agreed to acquire Soliton, which is commercialising a cellulite treatment based on research at University of Texas.
Soliton, a US-based developer of a medical device to treat cellulite based on research at University of Texas’ MD Anderson Cancer Center, has agreed to an acquisition by Allergan Aesthetics, a subsidiary of pharmaceutical firm AbbVie.
Allergan will pay $22.60 per share in cash for each outstanding share of Soliton, valuing the latter at approximately $550m. The merger has been approved by both boards of directors, but remains subject to customary closing conditions.
The deal follows regulatory clearance…
